LACIPIL

This brand name is authorized in Brazil, Croatia, Estonia, Italy, Lithuania, Mexico, Poland, Romania, Singapore, Spain, Turkey.

Active ingredients

The drug LACIPIL contains one active pharmaceutical ingredient (API):

1	Lacidipine UNII 260080034N - LACIDIPINE
	Lacidipine is a specific and potent calcium antagonist with a predominant selectivity for calcium channels in the vascular smooth muscle. Its main action is to dilate peripheral arterioles, reducing peripheral vascular resistance and lowering blood pressure.
	Read more about Lacidipine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C08CA09	Lacidipine	C Cardiovascular system → C08 Calcium channel blockers → C08C Selective calcium channel blockers with mainly vascular effects → C08CA Dihydropyridine derivatives
Discover more medicines within C08CA09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	510604401115317
EE	Ravimiamet	1073001, 1073023, 1122567, 1122578, 1834343, 1834354
ES	Centro de información online de medicamentos de la AEMPS	59778
HR	Agencija za lijekove i medicinske proizvode	HR-H-256476147, HR-H-365232222
IT	Agenzia del Farmaco	027830037, 027830052, 039331018, 042211019
LT	Valstybinė vaistų kontrolės tarnyba	1002670, 1002671, 1003564, 1003565, 1065682, 1093492, 1093493
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	512M94
PL	Rejestru Produktów Leczniczych	100000764, 100036495, 100036503
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65175001, W65175002, W65175003
SG	Health Sciences Authority	07934P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699522092628, 8699522092635